Gosuranemab

Gosuranemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MAPT, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Gosuranemab (BIIB092) is a humanized IgG4 monoclonal anti-antibody targeting the N-terminal tau protein (eTau). The basic principle of this treatment method is based on the hypothesis that eTau is involved in the spread of pathological diseases.

Target	MAPT
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human, Mouse
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1788032-39-2
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on MAPT

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue